CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 62 filers reported holding CATALYST PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $744,000 | +148.0% | 106,172 | +193.0% | 0.11% | +180.0% |
Q1 2022 | $300,000 | +85.2% | 36,241 | +51.5% | 0.04% | +100.0% |
Q4 2021 | $162,000 | +18.2% | 23,928 | +0.3% | 0.02% | +33.3% |
Q2 2021 | $137,000 | -67.3% | 23,855 | -73.8% | 0.02% | -78.6% |
Q1 2021 | $419,000 | +24.7% | 90,890 | -9.7% | 0.07% | +27.3% |
Q4 2020 | $336,000 | +1.8% | 100,605 | +17.4% | 0.06% | -33.7% |
Q1 2020 | $330,000 | -53.1% | 85,680 | -54.3% | 0.08% | +1.2% |
Q4 2019 | $703,000 | +282.1% | 187,496 | +441.3% | 0.08% | +228.0% |
Q3 2019 | $184,000 | +82.2% | 34,638 | +32.1% | 0.02% | +127.3% |
Q2 2019 | $101,000 | -86.8% | 26,220 | -87.1% | 0.01% | -73.8% |
Q3 2018 | $767,000 | -35.4% | 202,845 | -46.7% | 0.04% | -28.8% |
Q2 2018 | $1,187,000 | +416.1% | 380,605 | +295.7% | 0.06% | +391.7% |
Q1 2018 | $230,000 | -81.0% | 96,196 | -79.9% | 0.01% | -85.4% |
Q3 2017 | $1,208,000 | +48.8% | 479,196 | -35.7% | 0.08% | +86.4% |
Q3 2016 | $812,000 | +84.5% | 745,077 | +20.2% | 0.04% | +83.3% |
Q2 2016 | $440,000 | – | 619,777 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANAKA CAPITAL MANAGEMENT INC | 589,883 | $590,000 | 1.38% |
Broadfin Capital, LLC | 8,200,000 | $8,610,000 | 0.96% |
Avoro Capital Advisors LLC | 1,141,149 | $1,198,000 | 0.24% |
CORRADO ADVISORS, LLC | 190,600 | $200,000 | 0.12% |
Baker Brothers Advisors | 5,102,153 | $5,357,000 | 0.05% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 756,311 | $794,000 | 0.04% |
Point72 Asset Management, L.P. | 2,272,816 | $2,386,000 | 0.02% |
AGRAN LIBBIE | 44,000 | $46,000 | 0.01% |
COMPTON CAPITAL MANAGEMENT INC /RI | 10,000 | $11,000 | 0.01% |
KENNEDY CAPITAL MANAGEMENT LLC | 233,171 | $245,000 | 0.00% |